相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical utility of 177Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity
Rahul V. Parghane et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Clinical efficacy of177Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A not-so-promising result compared to GEP-NETs
Sandip Basu et al.
WORLD JOURNAL OF NUCLEAR MEDICINE (2020)
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
Carolien M. Beukhof et al.
BMC CANCER (2019)
'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'
Swayamjeet Satapathy et al.
CLINICAL ENDOCRINOLOGY (2019)
Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
Steven P. Weitzman et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2019)
Novel use of 177Lu-DOTA-RGD2 in treatment of 68Ga-DOTA-RGD2-avid lesions in papillary thyroid cancer with TENIS
Ashwin Singh Parihar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Methodological quality and synthesis of case series and case reports
Mohammad Hassan Murad et al.
BMJ EVIDENCE-BASED MEDICINE (2018)
SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival
Lisa H. de Vries et al.
ENDOCRINE (2018)
Use of 177Lu-dotatate in the treatment of iodine refractory thyroid carcinomas
P. Olivan-Sasot et al.
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR (2017)
Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues
Ali Salavati et al.
SEMINARS IN NUCLEAR MEDICINE (2016)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE
Cigdem Soydal et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2016)
Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer?
Fernanda Vaisman et al.
CLINICAL NUCLEAR MEDICINE (2015)
Medullary Thyroid Carcinoma (MTC) Treated With 177Lu-DOTATATE PRRT A Report of Two Cases
William Makis et al.
CLINICAL NUCLEAR MEDICINE (2015)
Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity
Rafal Czepczynski et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2015)
Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
Alfredo Campenni et al.
ENDOCRINE (2015)
Somatostatin Receptor Imaging in Non–131I-Avid Metastatic Differentiated Thyroid Carcinoma for Determining the Feasibility of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE
Bhargavi Jois et al.
CLINICAL NUCLEAR MEDICINE (2014)
Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients
Annibale Versari et al.
THYROID (2014)
Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?
M. Oe. Oeksuez et al.
DIAGNOSTIC AND INTERVENTIONAL IMAGING (2014)
Radionuclide Therapy in Neuroendocrine Tumours: A Systematic Review
K. Y. Gulenchyn et al.
CLINICAL ONCOLOGY (2012)
The Problem of the Patient with Thyroglobulin Elevation but Negative Iodine Scintigraphy: The TENIS Syndrome
Edward B. Silberstein
SEMINARS IN NUCLEAR MEDICINE (2011)
Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma
S. I. Sherman
CLINICAL ONCOLOGY (2010)
[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer Long-term Results of a Phase 2 Clinical Trial
Fabienne Iten et al.
CANCER (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines
P. K. Julka et al.
BRITISH JOURNAL OF RADIOLOGY (2008)
Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope
Hari A. Deshpande et al.
CURRENT OPINION IN ONCOLOGY (2008)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Current management of medullary thyroid cancer
Rebecca S. Sippel et al.
ONCOLOGIST (2008)
New therapeutic approaches to treat medullary thyroid carcinoma
Martin Schlumberger et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer:: A phase II clinical trial
Fabienne Iten et al.
CLINICAL CANCER RESEARCH (2007)
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy
C. Durante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans
M Gabriel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas
L Bodei et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms
JL Pasieka et al.
SURGERY (2004)
Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer:: a pilot study
MPM Stokkel et al.
NUCLEAR MEDICINE COMMUNICATIONS (2004)
The role of combined imaging in metastatic medullary thyroid carcinoma:: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy
ZR Gao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer
F Santini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
111In- and 90Y-DOTA-lanreotide:: Results and implications of the MAURITIUS trial
I Virgolini et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer
R Görges et al.
THYROID (2001)
Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide:: a pilot study
C Waldherr et al.
NUCLEAR MEDICINE COMMUNICATIONS (2001)
Toxicity of high-activity In-111-Octreotide therapy in patients with disseminated neuroendocrine tumours
ME Caplin et al.
NUCLEAR MEDICINE COMMUNICATIONS (2000)
分享论文
